Evidence map›Paper›PMID 42589573›Full record

ReviewInternational journal of molecular sciences2026

Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features.

Sara Allushi, Mariarita Virgulti, Giovanna Blaconà, Giampiero Ferraguti, Adriana Eramo, Marco Lucarelli

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara AllushiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0009-0007-1432-1226
Mariarita VirgultiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0009-0009-0435-0765
Giovanna BlaconàDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-1955-820X
Giampiero FerragutiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-6129-4071
Adriana EramoDepartment of Oncology and Molecular Medicine, Italian Institute of Health, 00161 Rome, Italy.
Marco LucarelliDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-5538-2494

Funding

Istituto Pasteur Project 2022-2023 Anna Tramontano (call 2020)Italian Cystic Fibrosis Research Foundation Project FFC#8/2021Ministero dell'università e della ricerca PRIN 2022 (project 2022FRSS2H, B53D23020270006)Sapienza University of Rome Research Projects 2021
6 · The paper itself

Abstract

Cystic fibrosis (CF) is one of the most common rare genetic diseases. It is caused by pathogenic variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. More than 2200 variants have been identified in the

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorMolecular Targeted TherapyAnimalsHumansMutationCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCFTRcystic fibrosisepigeneticsmodulatorstargeted therapy

Identifiers

PMID42589573
PMCPMC13467090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.